A novel inhibitory role for CREG-mediated signalling in cardiac hypertrophy?

Review

Rodney J Dilley. J Hypertens. 2004 Aug.

. 2004 Aug;22(8):1469-71.

doi: 10.1097/01.hjh.0000133741.00738.a2.

No abstract available

Comment on

CREG, a new regulator of ERK1/2 in cardiac hypertrophy.
Xu L, Liu JM, Chen LY. Xu L, et al. J Hypertens. 2004 Aug;22(8):1579-87. doi: 10.1097/01.hjh.0000133717.48334.cf. J Hypertens. 2004. PMID: 15257182

Negative regulators of cardiac hypertrophy.
Hardt SE, Sadoshima J. Hardt SE, et al. Cardiovasc Res. 2004 Aug 15;63(3):500-9. doi: 10.1016/j.cardiores.2004.03.015. Cardiovasc Res. 2004. PMID: 15276475 Review.
Targeted inhibition of ANKRD1 disrupts sarcomeric ERK-GATA4 signal transduction and abrogates phenylephrine-induced cardiomyocyte hypertrophy.
Zhong L, Chiusa M, Cadar AG, Lin A, Samaras S, Davidson JM, Lim CC. Zhong L, et al. Cardiovasc Res. 2015 May 1;106(2):261-71. doi: 10.1093/cvr/cvv108. Epub 2015 Mar 13. Cardiovasc Res. 2015. PMID: 25770146 Free PMC article.
[Signal transduction of JAK-STAT pathway].
Omura T, Yoshiyama M, Yoshikawa J. Omura T, et al. Nihon Rinsho. 2000 Jan;58 Suppl 1:206-9. Nihon Rinsho. 2000. PMID: 11026265 Review. Japanese. No abstract available.
The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy.
Buitrago M, Lorenz K, Maass AH, Oberdorf-Maass S, Keller U, Schmitteckert EM, Ivashchenko Y, Lohse MJ, Engelhardt S. Buitrago M, et al. Nat Med. 2005 Aug;11(8):837-44. doi: 10.1038/nm1272. Epub 2005 Jul 17. Nat Med. 2005. PMID: 16025126
Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.
Lister K, Autelitano DJ, Jenkins A, Hannan RD, Sheppard KE. Lister K, et al. Cardiovasc Res. 2006 Jun 1;70(3):555-65. doi: 10.1016/j.cardiores.2006.02.010. Epub 2006 Feb 14. Cardiovasc Res. 2006. PMID: 16533503